Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00042068 · ClinicalTrials.gov registry record · Phase 3
A Multi-Center Trial to Compare Three Doses of Meloxicam and Placebo in Patients With Rheumatoid Arthritis
A Phase 3 study of Arthritis, Rheumatoid, sponsored by Boehringer Ingelheim.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,000
- Enrollment target
- 20
- Study locations
NCT00042068 is a Phase 3 study of Arthritis, Rheumatoid that has completed, run by Boehringer Ingelheim. The registered enrollment target is 1,000 participants, above the 604-participant average among 27 other Arthritis, Rheumatoid trials with a reported enrollment target (66% higher). The trial reports 20 study locations across 8 states.
The verdict
NCT00042068, a Phase 3 study of Arthritis, Rheumatoid, has completed, sponsored by Boehringer Ingelheim.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
A 12-week trial consisting of 5 visits (6 if follow up is needed) to find out how effective and safe three different doses of meloxicam are compared with placebo in Rheumatoid Arthritis. Patient will take one dose of study medication daily.
Conditions Studied
Interventions
- DRUG Meloxicam
Study Locations (20)
California
- Boehringer Ingelheim Investigational Site - Los Angeles
- Boehringer Ingelheim Investigational Site - Pasadena
- Suite 100 - Rancho Cucamonga
- Boehringer Ingelheim Investigational Site - Rancho Mirage
- Suite 208 - San Diego
- Suite 202 - San Diego
- Suite 301 - San Leandro
- Suite A - Santa Maria
- Westlake Medical Research - Westlake Village
Arizona
- #106 - Glendale
- Suite 601 - Phoenix
- Suite 201 - Phoenix
Alabama
- Suites 570 (research) & 600 (PI) - Huntsville
- Suite 200 - Montgomery
Florida
- Boehringer Ingelheim Investigational Site - Delray Beach
- Boehringer Ingelheim Investigational Site - Gainsville
Alaska
- Suite 140 - Anchorage
Colorado
- Suite 200 - Colorado Springs
Connecticut
- Suites 205 & 206 - Danbury
District of Columbia
- Suite 300 - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,000 participants |
| Start Date | 2002-06 |
| Est. Completion | 2003-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00042068
The ClinicalTrials.gov registry entry for NCT00042068 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 604-participant average among 27 other Arthritis, Rheumatoid trials with a reported enrollment target (66% higher). The listed sponsor is Boehringer Ingelheim, which has 515 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Arthritis, Rheumatoid appearing as the primary indexed condition, and to 1 intervention - of which Meloxicam is the first listed.
NCT00042068 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Arizona, Alabama.
Frequently Asked Questions
What is clinical trial NCT00042068 about?
NCT00042068 is a clinical study titled "A Multi-Center Trial to Compare Three Doses of Meloxicam and Placebo in Patients With Rheumatoid Arthritis". A 12-week trial consisting of 5 visits (6 if follow up is needed) to find out how effective and safe three different doses of meloxicam are compared with placebo in Rheumatoid Arthritis. Patient will take one dose of study medication daily.
What is the current status of trial NCT00042068?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,000 participants. The study started on 2002-06. Estimated completion is 2003-07.
What conditions does trial NCT00042068 study?
This clinical trial studies the following conditions: Arthritis, Rheumatoid.
What interventions are being tested in trial NCT00042068?
The interventions under investigation include: Meloxicam (DRUG).
Who is sponsoring clinical trial NCT00042068?
This trial is sponsored by Boehringer Ingelheim, which has 515 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00042068 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arizona, California, Colorado. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Arthritis, Rheumatoid
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study Comparing 2 Doses Of CP-690,550 Vs. Placebo For The Treatment Of Rheumatoid Arthritis In Patients On Other Background Arthritis Medications
COMPLETED · Phase 3
-
Golimumab in Rheumatoid Arthritis Participants With an Inadequate Response to Etanercept (ENBREL) or Adalimumab (HUMIRA)
COMPLETED · Phase 3
-
COX-2 Inhibitor Study In Patients With Rheumatoid Arthritis
COMPLETED · Phase 3
-
Long-term Assessment of Safety and Efficacy of BI 695501 in Patients With Rheumatoid Arthritis
COMPLETED · Phase 3
-
Long-term Safety and Efficacy of ABP 501 in Subjects With Moderate to Severe Rheumatoid Arthritis
COMPLETED · Phase 3
-
BI 695501 Compared to Adalimumab in Patients With Active Rheumatoid Arthritis
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.